Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
microRNA 21 | 0.363 | 0.846 |
|
group | 0.100 | None | 0.979 | 243 | 0 | 2007 | 2020 | |||||||||
|
H3 histone pseudogene 10 | 0.350 | 0.846 |
|
group | 0.100 | None | 0.913 | 172 | 0 | 1995 | 2019 | |||||||||
|
cytochrome c oxidase subunit II | 0.352 | 0.962 |
|
group | 0.100 | None | 0.975 | 163 | 0 | 1998 | 2020 | |||||||||
|
MT-CO2 pseudogene 12 | 0.368 | 0.962 |
|
group | 0.100 | None | 0.973 | 147 | 0 | 1998 | 2020 | |||||||||
|
POU class 5 homeobox 1 pseudogene 3 | 0.452 | 0.808 |
|
group | 0.100 | None | 0.992 | 122 | 0 | 2003 | 2020 | |||||||||
|
POU class 5 homeobox 1 pseudogene 4 | 0.452 | 0.808 |
|
group | 0.100 | None | 1.000 | 122 | 0 | 2003 | 2020 | |||||||||
|
HOX transcript antisense RNA | 0.475 | 0.769 |
|
group | 0.100 | None | 0.965 | 115 | 4 | 2010 | 2020 | |||||||||
|
microRNA 34a | 0.421 | 0.846 |
|
group | 0.100 | None | 0.973 | 111 | 0 | 2007 | 2019 | |||||||||
|
CXADR pseudogene 1 | 0.463 | 0.846 |
|
group | 0.100 | None | 0.981 | 106 | 0 | 2003 | 2020 | |||||||||
|
CD24 molecule | 0.472 | 0.769 |
|
group | 0.100 | None | 0.981 | 103 | 0 | 2001 | 2020 | |||||||||
|
metastasis associated lung adenocarcinoma transcript 1 | 0.435 | 0.846 |
|
group | 0.100 | None | 0.956 | 91 | 1 | 2003 | 2020 | |||||||||
|
microRNA 155 | 0.384 | 0.885 |
|
group | 0.100 | None | 0.989 | 90 | 0 | 2006 | 2020 | |||||||||
|
T cell receptor beta variable 20/OR9-2 (non-functional) | 0.403 | 0.923 |
|
group | 0.100 | None | 0.977 | 86 | 0 | 1987 | 2020 | |||||||||
|
long intergenic non-protein coding RNA 1194 | 0.470 | 0.769 |
|
group | 0.100 | None | 1.000 | 82 | 0 | 1975 | 2020 | |||||||||
|
microRNA 145 | 0.431 | 0.846 |
|
group | 0.100 | None | 0.987 | 76 | 0 | 2003 | 2019 | |||||||||
|
H3 histone pseudogene 23 | 0.443 | 0.769 |
|
group | 0.100 | None | 0.951 | 61 | 0 | 1999 | 2018 | |||||||||
|
KLRC4-KLRK1 readthrough | 0.469 | 0.769 |
|
group | 0.100 | None | 0.982 | 57 | 0 | 2002 | 2019 | |||||||||
|
microRNA 221 | 0.449 | 0.846 |
|
group | 0.100 | None | 0.982 | 57 | 0 | 2007 | 2019 | |||||||||
|
microRNA 146a | 0.398 | 0.885 |
|
group | 0.100 | None | 0.893 | 56 | 1 | 2008 | 2020 | |||||||||
|
interferon alpha 1 | 0.371 | 0.923 |
|
group | 0.100 | None | 0.982 | 55 | 1 | 1993 | 2019 | |||||||||
|
interferon alpha 13 | 0.374 | 0.923 |
|
group | 0.100 | None | 0.982 | 55 | 0 | 1993 | 2019 | |||||||||
|
TERT 5' regulatory region | 0.464 | 0.731 |
|
group | 0.100 | None | 0.981 | 52 | 0 | 2003 | 2019 | |||||||||
|
cancer/testis antigen 1B | 0.507 | 0.731 |
|
group | 0.100 | None | 0.980 | 51 | 0 | 2000 | 2020 | |||||||||
|
cancer/testis antigen 1A | 0.508 | 0.731 |
|
group | 0.100 | None | 0.980 | 50 | 0 | 2000 | 2020 | |||||||||
|
Cbl proto-oncogene like 2 | 0.476 | 0.808 |
|
group | 0.100 | None | 0.957 | 47 | 0 | 2003 | 2020 |